ADAM10 and head and neck cancer: Treatment with silibinin, a plant-based flavonoid, upregulated miR-494 in head and neck cancer, which downregulated ADAM10 (a disintegrin and metalloprotease domain 10) and BMI1 (B lymphoma Mo-MLV insertion region 1 homolog), resulting in inhibition of tumor growth and self-renewal properties [110].